These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 20048171)

  • 81. Somatic mutations in arachidonic acid metabolism pathway genes enhance oral cancer post-treatment disease-free survival.
    Biswas NK; Das S; Maitra A; Sarin R; Majumder PP
    Nat Commun; 2014 Dec; 5():5835. PubMed ID: 25517499
    [TBL] [Abstract][Full Text] [Related]  

  • 82. [Anesthesia problems of patients with malignant oral neoplasms undergoing inductive chemotherapy protocol and surgery].
    Cianfriglia F; Manieri A; Mazzitelli MR; Faglieri N; Scinto F; Galfano M; Aloe L
    G Anest Stomatol; 1990; 19(3):15-20. PubMed ID: 2079233
    [TBL] [Abstract][Full Text] [Related]  

  • 83. An aid to the selection of chemotherapy regimens for oral cavity carcinomas. Early results of a study of 5-year survival based on antioncogram selection of anti-cancer drugs.
    Metelmann HR; Wolff K; Jonas S; Schlesinger S; Marin A
    Int J Oral Maxillofac Surg; 1990 Feb; 19(1):44-6. PubMed ID: 2110959
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Letter to the editor "Long-term outcomes of neo-adjuvant chemotherapy on borderline resectable oral cavity cancers: Real-world data of 3266 patients and implications for clinical practice".
    Selvan ST
    Oral Oncol; 2024 Sep; 156():106943. PubMed ID: 38991395
    [No Abstract]   [Full Text] [Related]  

  • 85. Comments on "Compositional and functional variations of oral microbiota associated with the mutational changes in oral cancer" by Yang et al.
    Gopinath D; Menon RK
    Oral Oncol; 2018 Mar; 78():216-217. PubMed ID: 29439898
    [No Abstract]   [Full Text] [Related]  

  • 86. ERK mediated upregulation of death receptor 5 overcomes the lack of p53 functionality in the diaminothiazole DAT1 induced apoptosis in colon cancer models: efficiency of DAT1 in Ras-Raf mutated cells.
    Thamkachy R; Kumar R; Rajasekharan KN; Sengupta S
    Mol Cancer; 2016 Mar; 15():22. PubMed ID: 26956619
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Sequencing the head and neck cancer genome: implications for therapy.
    Sun W; Califano JA
    Ann N Y Acad Sci; 2014 Dec; 1333():33-42. PubMed ID: 25440877
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Neoadjuvant chemotherapy in head and neck cancer: should it be revisited?
    Specenier PM; Vermorken JB
    Cancer Lett; 2007 Oct; 256(2):166-77. PubMed ID: 17673364
    [TBL] [Abstract][Full Text] [Related]  

  • 89. Chemotherapy for Oral Cancer.
    Hartner L
    Dent Clin North Am; 2018 Jan; 62(1):87-97. PubMed ID: 29126496
    [TBL] [Abstract][Full Text] [Related]  

  • 90. Functional p53 status as a biomarker for chemotherapy response in oral-cavity cancer.
    Mroz EA; Rocco JW
    J Clin Oncol; 2010 Feb; 28(5):715-7. PubMed ID: 20048171
    [No Abstract]   [Full Text] [Related]  

  • 91. TP53 mutations and pathologic complete response to neoadjuvant cisplatin and fluorouracil chemotherapy in resected oral cavity squamous cell carcinoma.
    Perrone F; Bossi P; Cortelazzi B; Locati L; Quattrone P; Pierotti MA; Pilotti S; Licitra L
    J Clin Oncol; 2010 Feb; 28(5):761-6. PubMed ID: 20048189
    [TBL] [Abstract][Full Text] [Related]  

  • 92. [p53 mutations and chemoresistance in oromaxillofacial squamous-cell carcinomas. The results of a molecular genetics study of p53 in metastatic oromaxillofacial tumors and an evaluation of the response to neoadjuvant chemotherapeutic treatment].
    Cutilli T; Papola F; Di Emidio P; Leocata P; Corbacelli A
    Minerva Stomatol; 1998; 47(1-2):1-9. PubMed ID: 9578641
    [TBL] [Abstract][Full Text] [Related]  

  • 93. [Neoadjuvant radiochemotherapy for squamous cell carcinoma of the oral cavity].
    Bootz F
    HNO; 2008 Feb; 56(2):183-4. PubMed ID: 18231725
    [No Abstract]   [Full Text] [Related]  

  • 94. The biomarker TP53 divides patients with neoadjuvantly treated esophageal cancer into 2 subgroups with markedly different outcomes. A p53 Research Group study.
    Kandioler D; Schoppmann SF; Zwrtek R; Kappel S; Wolf B; Mittlböck M; Kührer I; Hejna M; Pluschnig U; Ba-Ssalamah A; Wrba F; Zacherl J
    J Thorac Cardiovasc Surg; 2014 Nov; 148(5):2280-6. PubMed ID: 25135238
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Prognostic value of p53, glutathione S-transferase pi, and thymidylate synthase for neoadjuvant cisplatin-based chemotherapy in head and neck cancer.
    Shiga H; Heath EI; Rasmussen AA; Trock B; Johnston PG; Forastiere AA; Langmacher M; Baylor A; Lee M; Cullen KJ
    Clin Cancer Res; 1999 Dec; 5(12):4097-104. PubMed ID: 10632346
    [TBL] [Abstract][Full Text] [Related]  

  • 96.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 97.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 98.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 99.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 100.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.